logo-loader
AIM:AVCT

Avacta Group PLC

Receive alerts
Market:
AIM
Price
-
Day Change
-
Market Cap:
-
52 weeks high
-
52 weeks low
-

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.